with a better prognosis. The defined population that ultimately underwent complete follow-up and analysis as planned comprised 1919 patients. The attritions and challenges in following the initial study plan highlight the complexity of this type of study and the difficulty in interpretation of trial data. Importantly, although there is a potential risk of malignancy when a woman is diagnosed with an adnexal mass, early removal has not been shown to positively affect survival.\textsuperscript{7} So far, no effective screening method for ovarian carcinoma has been developed.\textsuperscript{5,8} Of the primary analysis population (n=1919), 12 (<1%) patients were diagnosed with malignant or premalignant neoplasms (five primary ovarian cancers, five ovarian low malignant potential tumours, and two metastatic tumours to the ovary).\textsuperscript{5} Notably, on retrospective review of the initial ultrasound images, many of the malignant lesions showed sonographic signs suggestive of malignancy and so were misclassified as benign. Ultrasound is an objective test and the operators’ expertise directly correlates with accuracy.\textsuperscript{9} This radiological variability is discussed by the study authors and they highlight that the proportion of patients judged to be suitable for follow-up was different between centres because of differences in patient characteristics and the level of experience of ultrasound examiners.\textsuperscript{6} Additionally, several centres were excluded from the analysis because of low enrolment. Clear definition of systematic and reproducible sonographic criteria that are generalisable and that will lead to diagnostic precision is imperative.

In summary, the current study supports conservative management of adnexal masses that are classified as benign on ultrasound imaging. Longer follow-up of the IOTA5 cohort study might further characterise the natural progression of masses characterised as benign by use of ultrasound and whether or not the incidence of unplanned surgical interventions, complications, or spontaneous resolution increase. The treatment algorithm for women with adnexal masses is based on clinical judgment and proper counselling. This approach takes into account the patients’ symptoms, physical findings, and test interpretation. The knowledge generated from the current trial could add value when counselling women with adnexal masses and could be reassuring to the patient when considering conservative management. The success of such management is dependent on good ultrasonography, and future efforts should continue to strive to improve predictive accuracy.

Taymaa May, *Amit Oza
Division of Gynecologic Oncology, Princess Margaret Cancer Center, University Health Networks, Toronto, ON, Canada (TM); and Division of Medical Oncology and Hematology, Princess Margaret Cancer Center, University Health Networks, Toronto, ON M5G 2M9, Canada (AO)
amit.oza@uhn.ca

We declare no competing interests.


Female representation among US National Comprehensive Cancer Network guideline panel members

The proportion of female physicians entering the field of oncology in the USA has steadily increased during the past two decades. Nearly half of US haematology-oncology fellowship trainees are women, and the proportion of female academic oncology faculty, which is increasing at the same rate as trainees, but with a
decade lag, now approaches 40%. There has also been an increase in female medical oncologists in Europe, and more than 40% of members of the European Society for Medical Oncology are women. Despite the increasing presence of women in academic oncology, gender disparity in the achievement of influential senior positions such as full professorships, departmental chairs, society board members, and executive leadership remains a concern globally.

Women face barriers to advancement in academic medicine compared with their male counterparts, hindering their subsequent rise to top-ranking roles. For example, women are offered substantially fewer early career sponsorship opportunities than men. Even after successful receipt of National Institutes of Health K-series awards, women ultimately publish fewer manuscripts and obtain less funding than men, independent of domestic responsibilities. With such limitations, it is not surprising that women are ultimately less likely to attain senior academic positions than are men. Yet, among the women who do overcome hurdles to achieve the conventional metrics for research success, commonly defined by the extent of publications and funding awarded, whether gender biases for selection of senior leadership positions exist remains unclear.

The National Comprehensive Cancer Network (NCCN) guidelines are the most widely used source of clinical practice information in oncology in the USA. These guidelines are routinely used to inform standard-of-care treatment decisions and reimbursement for off-label cancer drugs. Disease-specific panel members involved in creating these guidelines are esteemed academic oncologists, including pathologists, radiation oncologists, surgical oncologists, and medical oncologists, from highly regarded cancer centres. Professional advancement into such a leadership position is an achievement that depends largely on research success and academic distinction.

In the absence of gender bias, we would expect the representation of women in influential positions, such as the NCCN guidelines panel of experts, to mirror the representation of successful female cancer researchers. To investigate this hypothesis, we compared the proportion of female NCCN guideline panel members to the proportion of female research authors of influential manuscripts supporting these guidelines.

We tabulated the number of female versus male NCCN guideline panel members for 22 disease sites, including solid tumours and haematological malignancies. Gender was first determined by review of first name and, if we were uncertain, we did additional internet searches to discern gender, using best guess, on the basis of pronoun descriptors or images on publicly available institutional websites. We randomly sampled 50 of the references used to support treatment recommendations within each NCCN guideline panel that consisted of original research, were US-based, and were published in 2005 or later. We recorded author genders for the first, second, and last authors using the same method as described for panel members. Authors were only counted once in the analysis in the case of multiple publications within a single guideline.

Using a binomial test, we examined whether the observed proportion of female panel members deviates significantly from the expected proportion on the basis of overall female authorship. We calculated a Pearson correlation coefficient to examine the extent to which the proportion of female authorship is associated with the gender composition across the NCCN guideline panels. Statistical tests were two-sided and p-values less than 0.05 were considered significant.

The proportion of female NCCN panel members did not differ significantly from that of authors of seminal articles supporting the guidelines (194 [29%] of 670 members vs 769 [30%] of 2530 authors; p=0.44).
There was also a significant linear relationship between female NCCN panel members and research authors (r=0.67, p=0.0006) across the various guidelines (figure). Cancers usually specific to women (breast, uterine, and ovarian cancers) had both the highest proportion of female panel members and authorship. Genitourinary cancers (with the exception of prostate cancer) tended to have fewer women on guideline panels when compared with the proportion of female authors. These are historically male-dominated specialties in the USA. B-cell lymphomas and myeloma had notably more women on their respective panels compared with the extent of female authorship.

Thus, despite some imbalances within disease sites, the composition of female NCCN panel members overall was consistent with that of a large sample of influential female cancer researchers. Across guidelines, authorship was positively correlated with the proportion of women selected as panel members. This finding suggests that as more women surmount barriers to achieve research success in academia, the proportion of women in influential leadership roles can increase accordingly, as exemplified in the female-specific subspecialties.

It is encouraging that selection of guideline panel members for the NCCN, a noteworthy resource in oncology practice in the USA, seems independent of gender bias. However, these findings should not detract from the known underlying gender gaps in research achievement among advancing academic faculty. The proportion of female NCCN panelists (29%) is less than the proportion of female academic oncologists overall (40%). Given that nearly 15 years in academic medicine are required before promotion to senior positions, NCCN panel members today would probably represent the proportion of female academic oncologists in an earlier generation. For example, in 2005, women only comprised 30% of academic haematology-oncology faculty. Previous data suggest that board membership for prominent oncology societies in the USA and Europe does fall slightly short of this goal, with women comprising roughly 25% of board members in 2016.

Our results indicate that the gender composition of NCCN cancer experts appropriately reflects the pool of successful researchers. As more women enter the academic oncology community, we expect that the percentage of women in senior leadership positions will continue to increase. However, this outcome depends primarily on efforts to bolster the academic experience and outcomes for the current cohort of female junior faculty members to ensure their research potential is realised.

*Angela K Green, Brooke Barrow, Peter B Bach
Center for Health Policy and Outcomes, Memorial Sloan Kettering Cancer Center, New York, NY 10065; USA

greena@mskcc.org

PBB reports grants from Kaiser Permanente, grants from the Laura and John Arnold Foundation, and grants from the National Institutes of Health (Core Grant P30 CA 008748), during the conduct of the study; personal fees from the American Society for Health-System Pharmacy, Gilead Pharmaceuticals, WebMD, Goldman Sachs, Defined Health, Vizient, Anthem, Exelixis Health Plan, Hematology Oncology Pharmacy Association, Novartis Pharmaceuticals, Janssen Pharmaceuticals, Third Rock Ventures, JHP Securities, and Genentech, and other from Foundation Medicine and Grant outside the submitted work. AKG and BIL declare no competing interests.